IPC분류정보
| 국가/구분 |
United States(US) Patent
등록
|
| 국제특허분류(IPC7판) |
|
| 출원번호 |
US-0852745
(1977-11-18)
|
|
발명자
/ 주소 |
- Krezanoski Joseph Z. (Los Altos CA)
|
| 출원인 / 주소 |
- Cooper Laboratories, Inc. (Palo Alto CA 02)
|
| 인용정보 |
피인용 횟수 :
133 인용 특허 :
0 |
초록
▼
Pharmaceutical vehicles for delivery of pharmacologically active chemical materials to mucous membranes, as well as pharmaceutically active compositions containing such vehicles, are provided. The pharmaceutical vehicles are clear, water-miscible, physiologically-acceptable, liquid compositions whic
Pharmaceutical vehicles for delivery of pharmacologically active chemical materials to mucous membranes, as well as pharmaceutically active compositions containing such vehicles, are provided. The pharmaceutical vehicles are clear, water-miscible, physiologically-acceptable, liquid compositions which gel to a thickened, non-flowing and adhering consistency at human body temperature. They are liquid at ambient room temperature and have a gel transition temperature in the range of from about 25°C. to about 40°C. Aqueous solutions of certain polyoxyethylene-polyoxypropylene condensates are suitable vehicles. Also provided are pharmaceutical compositions containing added pharmacologically active chemical material, i.e., a drug or medicament. A method of delivering the drug or medicament to a mucous membrane is also provided. This is a continuation of application Ser. No. 661,612, filed Feb. 26, 1976, now U.S. Pat. No. 4,100,271.
대표청구항
▼
A pharmaceutical composition for medicinally treating a mucous membrane or eye condition requiring pharmacologic treatment, comprising: (a) a pharmacologically effective amount of a chemical material which is pharmacologically active against said condition; said material being selected from the grou
A pharmaceutical composition for medicinally treating a mucous membrane or eye condition requiring pharmacologic treatment, comprising: (a) a pharmacologically effective amount of a chemical material which is pharmacologically active against said condition; said material being selected from the group consisting of dexamethasone, pilocarpine HCl, phenylephrine HCl, clofazimine, pimaricin, amphotericin, neomycin sulfate, chloramphenicol, bacitracin, sulfacetamide, gentamycin, and polymixin B sulfate; (b) from about 10% to about 26% by weight of a polyoxyethylene-polyoxypropylene block copolymer in which the number of polyoxyethylene units is at least about 50% of the total number of monomeric units in the total molecule, the block copolymer having an average molecular weight of from about 7,500 to about 15,500, a room temperature solubility in water of greater than about 10 grams per 100 ml. of water, and a cloud point in 1% aqueous solution of at least about 100°C.; (c) up to about 10% sodium chloride equivalent of at least one water-soluble compatible salt selected from the group consisting of sodium halide, sodium sulfate, sodium nitrate, sodium phosphate, potassium halide, potassium sulfate, potassium nitrate, potassium phosphate, and mixtures thereof; (d) an effective amount of a preservative to afford protection to the composition against bacterial contamination selected from the group consisting of benzalkonium chloride, a sodium salt of ethylenediaminetetraacetic acid, sorbic acid, and alkali metal salt of sorbic acid, boric acid, an alkali metal salt of boric acid, thimerosal sodium, phenylmercuric acetate, a methyl, ethyl or propyl ester of para-aminobenzoic acid, and mixtures thereof; and (e) from about 74% to about 90% by weight water; the composition having a pH of from about 6.0 to about 8.5 and a gel transition temperature in the range of from about 25°C. to about 40°C.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.